Uehara Y, Numabe A, Kawabata Y, Nagata T, Iwai J, Matsuoka H, Yagi S, Takabatake Y, Sugimoto T
2nd Department of Medicine, University of Tokyo, Japan.
J Cardiovasc Pharmacol. 1991 Jul;18(1):158-66. doi: 10.1097/00005344-199107000-00021.
We designed experiments to investigate the effects of cicletanine, a novel antihypertensive drug, on medial hypertrophy in Dahl rats susceptible to salt-induced hypertension (Dahl S rats). Cicletanine treatment (500 mg of cicletanine/kg of chow) for 6 weeks lowered blood pressure by 19% in Dahl S rats challenged with a high-salt (4%) diet. The blood pressure reduction was associated with a significant decrease in weight of the aortic vessels. Morphological examination revealed that this treatment decreased medial hypertrophy and expansion of intimal tissue, in concert with resolution of the periarteritis in the intrarenal arteries. In fact, the content of actin in the aortic wall, analyzed by SDS-PAGE, was decreased significantly with this treatment and myosin content was reduced to the same extent as well. Moreover, cicletanine per se lowered protein synthesis in randomly cycling cultured vascular smooth muscle cells (VSMCs) from Sprague-Dawley rats. Actin formation by VSMCs was decreased with cicletanine. Thus, these data indicate that chronic cicletanine treatment produces regression of the medial hypertrophy in Dahl S rats. Direct inhibitory effects on cytoskeleton protein synthesis, as well as its antihypertensive action, are partly responsible for this regression in vivo.
我们设计了实验,以研究新型抗高血压药物西氯他宁对盐敏感性高血压易感的 Dahl 大鼠(Dahl S 大鼠)血管中层肥厚的影响。用高盐(4%)饮食刺激 Dahl S 大鼠,给予西氯他宁治疗(500 mg 西氯他宁/千克饲料)6 周后,大鼠血压降低了 19%。血压降低与主动脉血管重量显著减轻有关。形态学检查显示,这种治疗减少了血管中层肥厚和内膜组织扩张,同时肾内动脉周围炎也得到缓解。事实上,通过 SDS-PAGE 分析,主动脉壁中肌动蛋白的含量在这种治疗后显著降低,肌球蛋白含量也降低到相同程度。此外,西氯他宁本身降低了来自 Sprague-Dawley 大鼠的随机循环培养血管平滑肌细胞(VSMC)中的蛋白质合成。西氯他宁可降低 VSMC 的肌动蛋白形成。因此,这些数据表明,长期给予西氯他宁可使 Dahl S 大鼠的血管中层肥厚消退。对细胞骨架蛋白合成的直接抑制作用及其抗高血压作用在一定程度上导致了体内这种消退。